Prinz Law

PayPal has advised e-book sellers that they must remove all erotica content off their websites.  The Silicon Valley IP Licensing Law Blog discussed the PayPal decision and the controversy that resulted in the following blog post:

http://www.siliconvalleyiplicensinglaw.com/paypal-launches-new-internet-controversy-over-decision-to-censor-erotica-content-sold-through-platform/

President Obama has announced the Consumer Privacy Bill of Rights initiative, as further discussed by the Silicon Valley Software Law Blog in the following blog post linked here:

http://www.siliconvalleysoftwarelaw.com/president-obama-unveils-new-consumer-privacy-initiative-the-consumer-privacy-bill-of-rights

Apple’s trademark dispute with Proview has become a two-front fight on both the local and international levels, as The Silicon Valley IP Licensing Law Blog explored in the following blog post:

http://www.siliconvalleyiplicensinglaw.com/apple-trademark-dispute-with-proview-becomes-a-global-fight/

SOPA Blackout protesters have succeeded in having tabling SOPA and its companion bill PIPA, as the Silicon Valley IP Licensing Law Blog discussed in the following blog post:

http://www.siliconvalleyiplicensinglaw.com/sopa-blackout-protesters-succeed-in-tabling-sopa-and-pipa-bills/

Is the Online Protection and Enforcement of the Digital Trade Act (“OPEN”) a better alternative to SOPA?  The Silicon Valley Software Law Blog explored this question in the blog post linked below:

http://www.siliconvalleysoftwarelaw.com/is-the-open-act-a-more-viable-alternative-to-sopa

What are the lessons Silicon Valley companies should take away from Apple’s trademark dispute over the use of the mark “iPad” in China?  The Silicon Valley IP Licensing Law Blog looks at the dispute and the lessons to be learned from the dispute in the following blog post:

http://www.siliconvalleyiplicensinglaw.com/lessons-for-silicon-valley-companies-in-apple-trademark-dispute/

The California Biotech Law Blog reported that the outlook for biotech in 2012 was expected to remain dreary, and that companies would continue to focus on acquisitions over IPOs in the following blog post:

 http://californiabiotechlaw.com/archives/biotech-ipos/ipo-outlook-for-biotech-remains-dreary-in-2012/